drugset / Trial / NCT05310968

Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction

NCT05310968

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Perforating artery territorial infarction (PAI) refers to a single ischemic lesion in a single perforating arterial territory and branch atheromatous disease (BAD) is an important type. BAD related stroke accounts for 10%-15% ischemic cerebral infarction and is closely related to early neurological deterioration (END). Among patients with single ischemic lesion in other study, dual antiplatelet (clopidogrel plus aspirin) did not significantly reduce the risk of recurrent stroke. The primary purpose of this study is to assess the efficacy and safety of tirofiban combined with aspirin versus placebo combined with aspirin in reducing the risk of stroke and END in patients with BAD.

Timeline

Start
2022-11-12
Primary completion
2025-02-17
Completion
2025-09-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirofiban Other / unclassified 0.1 ug/kg Intravenous
Background Aspirin Small molecule 100 mg